In8bio started at Buy by Wainwright

 H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of IN8bio with a “Buy” rating and a price target of $14.

“In8bio is a clinical-stage biopharmaceutical company focused on developing γδ (gamma-delta) T cell therapies as a cancer treatment. γδ T cells that make up less than 10% of circulating T cells expand rapidly to infection and stress-induced antigen and mount a potent cytotoxic response,” wrote Ramakanth in the research note. “In our view, γδ T cell therapy is advantageous over conventional chimeric antigen receptor (CAR)-T cell therapy because of its excellent safety profile, combined properties of both the adaptive and innate immune systems, as well as its ability to treat solid tumors including those resistant to traditional immunotherapy. IN8bio’s lead candidate, INB-200, an autologous chemo-resistant γδ T cell therapy is being evaluated in a Phase 1 study as a therapy for newly diagnosed Glioblastoma Multiforme (GBM). Positive initial data showed acceptable safety and tolerability profile, and we expect additional clinical data including efficacy in 2H22.”

https://pulse2.com/in8bio-inab-stock-why-it-surged-over-30-today/